On June 6, 2019, MSD presented a webinar focused on the following:
Innovative cancer treatment in early settings holds tremendous promise, but appropriate valuation requires consideration of early endpoints and quality of life benefits. What value do we place in sparing patients the experience of living through metastatic disease? This webinar will introduce the concepts in advance of the MSD Idea Factory at HTAi Annual Meeting in Cologne and allow attendees to interact with the speakers by sending in questions to be answered.
This webinar provided a first introduction to the discussion questions that will be work-shopped at the MSD Idea Factory on 17 June 2019 (Cologne).
• How can we ensure patient benefits (e.g. avoidance of metastatic disease) in early treatment are captured in valuation of innovative cancer treatment?
• How do we address uncertainty that payers may face when comparing earlier and later treatments?
• What contractual process can we propose to ensure rapid access where early treatment shows clinical benefit (e.g. adaptive pathways)?
Participants of this webinar were able to:
• introduce the concepts of MSD’s Idea Factory session on 17 June 2019,
• enable the HTAi community to explore the content presented by the speakers in more detail via Q&A, and
• introduce the topics for ideation at the Idea Factory session to enable participants to prepare and consider these challenges in advance.
Amaris Consulting presented a webinar focused on the following:
The continuous evolution of technologies provides the foundations on which innovation in healthcare can thrive. Increased development and adoption of technological solutions on personal and institutional levels create an unprecedented opportunity for outcomes data collection, its integration, exchange and analysis. This webinar discusses the potential of technological innovation to transform value-based healthcare and the way health technologies are assessed.
Structure of Session
Topic 1: Innovations in healthcare: general overview & direction (Speaker: Petar Atanasov).
Topic 2: Innovative technologies and real-world evidence (RWE) collection (Speaker: Robert Chu)
Topic 3: Innovative contracting & the role of technologies (Speaker: Anthony Berthon)
Topic 4: Role of innovative technologies in the delivery of value-based healthcare (Speaker: Lisa Hollins)
Topic 5: The role and assessment of predictive analytics / machine learning-based health technologies (Speaker: Mehdi Benchoufi)
Outcomes and Objectives: This multidisciplinary webinar combines the views of experts in their fields and delivers a comprehensive overview of how innovation may transform the way we assess value of health technologies and ultimately make decisions on reimbursement. The session will also provide non-experts with a fundamental understanding of key concepts and benefits associated with disruptive technologies entering the field. Our objective is to deliver the webinar in a way which is engaging to the diversity of stakeholders that are actively involved in the areas of health technology value assessment and more broadly with the delivery of value-based healthcare.
This webinar discussed a range of topics which could be of interest to: HTA decision makers; Drug and medical device manufacturers; Outcomes researchers; Policy makers; Digital health specialists; Value-based healthcare specialists
On May 28, 2019, Pharmerit presented a webinar based on the following:
Europe is striving towards greater cooperation in Health Technology Assessment (HTA). Opportunities exist to create synergies through mutual information sharing among member states to support national HTAs. Although there is increasing focus on the uptake of EUnetHTA joint clinical assessments, challenges need to be identified and addressed, before current efforts can translate into seamless and efficient HTA harmonization in Europe.
This webinar presented an overview of current trends, and findings based on a qualitative comparison of the methodologies used in the JCA (within the JA3 framework) and the appraisals performed by the national HTA bodies (NICE, G-BA and HAS) in oncology.
Participants of the webinar were able to:
- Deep-dive into EUnetHTA JA3 assessments and their evolution over time
- Draw a comparison between JCAs and appraisals performed by the national HTA bodies (NICE, G-BA and HAS) in oncology
- Gain a real-world update of the ongoing discussions around JCAs
- Discern the potential for a joint HTA in Europe, in terms of opportunities and challenges
- Moderator: Rosemary Jose, Director, Strategic Market Access, Pharmerit International
- Co-Moderator: Amrita Ostawal, Associate Director, Strategic Market Access, Pharmerit International